Clinical Trial

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Trial Details
NCT Number NCT07179692
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer
Enrollment 108 participants
Start Date 2025-09-12
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02